Re-induction with venetoclax combinations or IDH inhibitors result in similar remission rates and lower treatment related morbidity among AML patients initially receiving intensive induction chemotherapy.
Skyler TaylorGuru Subramanian Guru MurthyLyndsey RunaasLaura C MichaelisKaren CarlsonEhab L AtallahSameem M AbedinPublished in: Leukemia research (2023)